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Abstract
Atherosclerosis is the main cause of myocardial infarction. This process 
involves a complex interplay between metabolic pathways governing lipid deposi-
tion, inflammatory and immune responses to oxidized lipids, and endothelial 
dysfunction. Myocardial infarction appears when these processes culminate with 
a thrombotic event. Markers of inflammation, such as C-reactive protein (CRP), 
myeloperoxidase (MPO) and leukocyte levels are strong predictors of cardiovas-
cular death, myocardial infarction, and stroke. This process involves a complex 
interplay between metabolic pathways governing lipid deposition, inflammatory 
and immune responses to oxidized lipids, and endothelial dysfunction. Myocardial 
infarction appears when these processes culminate with a thrombotic event. 
Markers of inflammation, such as C-reactive protein (CRP), myeloperoxidase 
(MPO) and leukocyte levels are strong predictors of cardiovascular death, myocar-
dial infarction, and stroke. This review will summarize the molecular and cellular 
links between inflammation and thrombosis in the context of myocardial infarc-
tion, which support the concept of a thrombo inflammatory state leading to the 
vessel obstruction and to the subsequent myocardial necrosis.
Keywords: thrombosis, inflammation, atherosclerosis
1. Introduction
Myocardial infarction is a form of coronary artery disease, in which the occlu-
sion of the coronary artery induces ischemia of the subsequent territory and 
eventually leads to the destruction of up to a billion myocardic cells.
Atherosclerosis is the main cause of myocardial infarction. This process 
involves a complex interplay between metabolic pathways governing lipid deposi-
tion, inflammatory and immune responses to oxidized lipids, and endothelial 
dysfunction.
Myocardial infarction appears when these processes culminate with a throm-
botic event. Markers of inflammation, such as C-reactive protein (CRP), myeloper-
oxidase (MPO) and leukocyte levels are strong predictors of cardiovascular death, 
myocardial infarction, and stroke [1].
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As the human heart cannot regenerate, the acute myocardial infarction is associ-
ated with the destruction of large proportion of myocardium that will lead to the 
development of a collagen scar. This process is associated with an evident inflamma-
tory reaction. This inflammatory reaction will lead to the chemotaxis of leukocytes 
that will be preferentially localized at the border of the necrotic myocardium. These 
leukocytes may lead to cytotoxic reactions that can increase the injured zone [2].
2. The role of inflammation in myocardial infarction
The acute pro-inflammatory process triggered by the onset of myocardial infarc-
tion consists in multiple processes such as the production of reactive oxygen species 
and DAMPs (damage associated molecular patterns) which are in fact the substrate 
for PRRs (pattern recognition receptors). These processes will eventually lead to 
the formation of cytokines and chemokines that will mediate the attraction of thee 
inflammatory cells to the border zone of the myocardial infarction.
After the onset of a myocardial infarction the healing process involves three 
important phases: the inflammatory response, the proliferation and in the end the 
maturation.
During the inflammatory response the necrotic cardiomyocytes release danger 
signals, called alarmins that will signalize some particular types of receptors called 
TLRs (toll-like receptors) and RAGE (receptor for advanced glycation end prod-
ucts), thus stimulating the immune cells, the endothelial ones and the fibroblasts to 
secrete chemokines and cytokines. The inflammatory phase is also characterized by 
the activation of the complement cascade. The complement cascade can be acti-
vated in three different manners: the classic pathway, the lectin and the alternate 
way [1–3]. These pathways all lead to the common pathway that results in opsoniza-
tion, subsequent inflammation attracting others phagocytes, or activation of thee 
cell killing membrane attack complex – Figure 1.
Figure 1. 
The complement cascade – https://www.sciencedirect.com/topics/medicine-and-dentistry/complement-system.
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The inflammatory process and the activation of the complement cascade deter-
mine the release of pro-inflammatory cytokines, such as Tumor Necrosis Factor 
(TNF)-α, IL-1β and IL-6.
A key role in the activation of the inflammatory reaction is played by the IL-1 
signaling pathway. This pathway stimulates the production of chemokines by fibro-
blasts and leukocytes, but inhibits the conversion of fibroblasts in myofibroblasts. 
Damaged myocardial cells release IL-1α, while IL-1β is upregulated after infarction. 
An important key for this mechanism is represented by the inflammasome, which 
triggers the activation of caspase-1 and thus transforms active pro-IL-1β into IL-1β. 
It was shown that the inflammasome can be found both in myocardial and in inter-
stitial cells in the ischemic myocardium. The pharmacological blockage of IL-1 or 
the genetic inhibition proved to reduce left ventricle remodelation after myocardial 
infarction [4, 5].
IL-6 is associated with both pro and anti-inflammatory effects. Myocardial 
infarction is associated with increased circulating IL-6. Some studies showed that 
the genetic polymorphisms of the IL-6 receptor signaling pathway may lead to a 
diminished plasma level of high-sensitivity C-reactive protein (hs-CRP) and thus 
may lead to the decrease of cardiovascular risk [6].
The post-infarction inflammatory response determines a chemokine upregulation, 
which are responsible for the recruitment of other leukocytes in the infarcted area.
The neutrophils are activated by CXC chemokines containing the Glu-Leu-Arg 
sequence (the ELR motif), such as CXCL8/IL-8, while the CC chemokines, such as 
monocyte chemo attractant protein-(MCP)-1/CCL2 and CCL7 attract monocytes. 
The phagocytosis is activated and the necrotic detritus is eliminated, so that the 
healing process may start. When the infiltrated neutrophils enter the apoptotic 
process, the inflammatory phase comes to an end [7].
From this moment on the apoptotic cells are scavenged by professional phago-
cytes, thus leading to a process called efferocytosis. This phase consists in the 
release of cytokines with anti-inflammatory effect such as IL-10 and TGF-β. These 
mediators induce an endogenous intracellular signal, such as Interleukin-receptor 
associated kinase-M that inhibits the pro-inflammatory process in the healing areas 
of the myocardium. The inhibition of inflammatory signaling and the removal of 
the inflammatory infiltrate is determined by the presence of inhibitory leukocyte, 
such as anti-inflammatory monocyte subpopulations and regulatory T cells [8].
The remaining cardiomyocytes in the infarct border zone secrete mediators with 
anti-inflammatory properties that lead to the diminishment of the affected area. 
If the inflammatory response is unrestrained or is very expansive, the result will 
consist in rapid left ventricle remodeling, which can be implicated in inducing heart 
failure in patients surviving an acute myocardial infarction.
When the proliferative phase of myocardial infarction has begun, the diminish-
ment of pro-inflammatory molecules such as IL-1β and Interferon-γ-inducible 
Protein (IP)-10 causes the transformation of fibroblasts in myofibroblasts. These 
compounds have an extensive endoplasmic reticulum and possess a contractile 
protein that is called α-smooth muscle actin (α-SMA) and are capable of inducing 
an increased synthesis of matrix protein [7–9].
When the proliferative phase comes to an end, the mature scar starts to form. 
The myofibroblasts enter apoptosis and matrix cross-linking occurs. This mecha-
nism seems to be mediated by the removal of growth factors, the inhibition of 
TGF-β mediated response and the modification of the composition of the matrix.
In the remaining healthy myocardium the fibroblasts may rest chronically active 
as s result of a pressure overload. This will induce the fibrosis of the myocardium 
and will lead to diastolic dysfunction.
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As inflammation plays a key-role in the pathogenesis of myocardial infarction, 
some authors thought that giving anti-inflammatory therapy to patients with acute 
coronary syndrome would be beneficial, but the results proved that treatment with 
corticosteroids or with NSAIDs is associated with a worsened outcome. Due to the non-
selective inhibition of the inflammatory cascade, these drugs have potentially cata-
strophic consequences. Therefore the current guidelines are against the use of broad 
range anti-inflammatory therapy in patients with acute coronary syndrome [10, 11].
A better understanding of the process of inflammation in myocardial infarction 
leads to the conclusion that targeted inhibition of selected inflammatory routes 
may add up to the protection of the vulnerable myocardium without harming the 
reparative response. There are studies that showed that a targeted neutralization of 
specific inflammatory mediators such as chemokines and cytokines can reduce the 
size of the infarction.
3. The role of thrombosis in myocardial infarction
Inflammation is responsible for inducing an active atheroclerotic plaque, but this 
plaque is not sufficient to induce a myocardial. After the plaque has ruptured, the 
hemostatic balance is impaired, thus leading to coronary thrombosis. The altera-
tions of the hemostatic balance consist in increased platelet adhesion, coagulation 
cascade activation and subsequent. Over-activated procoagulation determines a 
thrombophillic status that can be acquired from complex patterns of inheritance or 
environmental risk factors.
The thrombotic events may be caused by an increase of different coagulation 
factors. Plasmatic fibrinogen is an important cardiovascular risk factor. It was 
proven that increased levels of Interleukin 6, may lead to an increased hepatic 
synthesis of fibrinogen, thus representing an important link between inflammation 
and thrombophilic status.
Thrombin or FIIa is a serin protease which has an important clotting effect. 
The importance of thrombin in the clotting anomalies is rather disputed. Some 
studies have shown that the concentration of thrombin in patients with coronary 
artery disease is normal and that it does not represent a predicting factor for 
vascular complications, while other researchers have stipulated that thrombin is 
one of the most important factors responsible for the thrombotic complications. 
Nevertheless, increased levels of thrombin are associated with the presence of 
denser thrombus structures, with a diminished permeability, which is resistant to 
fibrinolysis [12–14].
Clotting factor XIII is involved in hemostasis, fibrinolysis, vascular remodeling 
and tissue repair. It is important to do the genotyping of factor XIII in order to assess 
the prothrombotic status because the existing data in the literature rest unclear. 
Clotting factor XIII is a pro-transglutaminase with tetrameric structure consisting 
of two active subunits A and two inhibitory/protective subunits B. The clotting 
factor XIII genotyping has shown that mixed FXIII heterozygous mutants (formed 
from a wild allele and a mutant one) were associated with increased levels of total 
and LDL-cholesterol and with elevated concentrations of CRP, while the other geno-
types of clotting factor XIII have not been correlated with these changes [15–18].
From our personal experience, from a clinical study including 60 patients with 
myocardial infarction, we found out that 25% of patients had heterozygous mutants 
of factor XIII (wild type + mutant type), the majority of them being elderly men. 
Almost one third of the patients with PAI-1 4G/4G genotype and a quarter of 
those with genotype 5G/5G were associated with heterozygous mutants of FXIII 
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(WT + MT); the combined 4G/5G genotype was associated only with wild-type 
FXIII. The clotting factor XIII genotyping realized during the current research has 
shown that mixed FXIII heterozygous mutants (formed from a wild allele and a 
mutant one) were associated with increased levels of total and LDL cholesterol and 
with elevated concentrations of C-reactive protein, while the other genotypes of 
clotting factor XIII have not been correlated with these changes – Figure 2.
These genomic changes appear to be responsible for the decreased permeability 
of the formed thrombus and for the inhibition of the fibrinolysis process, which 
explains the higher incidence of acute coronary syndromes and complex coronary 
artery lesions in type 2 diabetic patients [19, 20].
The atherothrombotic complications may be caused also by a modification in 
fibrinolysis. The fibrinolysis is initiated by the conversion of plasminogen in plas-
min, a process which is mediated mainly by the tisular plasminogen activator (tPA).
The plasminogen activator inhibitor type 1 (PAI-1) is the primary inhibitor of the 
fibrinolysis, which acts by forming a complex with tPA. PAI-1 gene is situated on the 
7th chromosome and contains 8 introns and 9 exons. The effect of PAI-1 is the down-
regulation of the fibrinolytic process as it inhibits the transformation of plasminogen 
to plasmin regulated by tissue-plasminogen activator and urokinase [21–23].
PAI-1 levels are proportional with the degree of the inflammatory process, 
induce atherosclerosis and are linked to the presence of metabolic syndrome. 
Obesity and diabetes mellitus type 2 are pathological conditions associated with 
increased PAI-1 levels that may lead to extensive atherosclerosis. Human CD 
34+ cells exert high levels of PAI-1 especially in patients with diabetes and micro 
vascular complications. High levels of PAI-1 are associated with visceral adiposity 
because this molecule is produced by ectopic fat depots. The inflammatory state 
conferred by the high PAI-1 levels cause a dysfunctional activity of the cytokines 
(IL-8, leukotriene B4) and can determine impaired monocyte migration [24].
There are 5 polymorphisms of the PAI-1 gene: 675 4G/5G, 844 A > G, Ala15Thr, 
Val17Ile and Asn195Ile. The 4G/5G polymorphism (the deletion/insertion of 
guanosine in the 675 position of the PAI-1 gene promoter) is a major genetic 
determinant of PAI-1 levels. Some authors have suggested that the 4G allele associa-
tion with other thrombophilic defects (factor V Leiden, prothrombin mutation, 
hyperhomocysteinemia, and decreased activity of protein C or S) increases the risk 
of thrombosis. In patients with coronary artery disease the presence of PAI-1 4G/4G 
genotype was associated with an increased risk of sudden death. When PAI-1 has 
an increased activity, the high circulating levels of PAI-1 may induce the persistence 
of microthrombi, therefore leading to a prothrombotic state in an early myorcardial 
infarction please, which will affect the short-term outcome of patients with acute 
coronary syndrome. Even more PAI-1 levels are linked to the degree of myocardial 
fibrosis that can lead to detrimental left ventricle remodeling and poor long-term 
prognosis [25–28].
From our personal experience from a research involving 60 patients with acute 
coronary syndrome, we found out that the majority of patients had the 4G/4G 
Figure 2. 
Identification of factor XIII Val34Leu polymorphism.
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Figure 3. 
The relationship between PAI-1 polymorphism and the plasmatic level of fibrinogen.
genotype, which was associated with elevated levels of glycated hemoglobin and 
with a high concentration of LDL cholesterol and fibrinogen and with multivessel 
atherosclerosis, while the other genotypes of PAI-1 were not correlated with these 
changes – Figures 3 and 4.
In our studied group, 65% of patients had the PAI-1 4G/4G genotype, while 15% 
of patients had a heterozygote 4G/5G genotype. Not only did PAI-1 4G/4G genotype 
associate more frequently with atherogenic dyslipidemia, but it also showed a slight 
direct correlation with the inflammatory parameters – Figure 5.
As a consequence we can assume that the prothrombotic status found in patients 
with myocardial infarction seems to be modulated by the genomic polymorphism 
of clotting factor XIII, which is responsible for the formation of a more stable 
cruoric thrombus which is more resistant to fibrinolysis. Even more, these patients 
show a deficiency of the endogenous fibrinolysis, which predisposes the develop-
ment of a thrombophilic status. This decrease in the thrombolytic process seems to 
derive from the genomic polymorphism of plasminogen activator inhibitor type 1. 
The most common genotype of PAI-1 associated with an increased cardiovascular 
risk is PAI-1 4G genotype. These polymorphisms are correlated with the presence 
of metabolic disorders and an abnormal inflammatory process in patients with 
acute coronary syndrome, thereby inducing an increased cardiovascular risk in 
these patients.
Figure 4. 
The relationship between PAI-1 polymorphism and the plasmatic level of LDL-cholesterol.
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In conclusion, a better understanding of the inflammatory and thrombotic pro-
cesses that lead to myocardial infarction can help improve the manner of treatment 
for this patients, thus increasing their quality of life and their prognostic.
Figure 5. 
Identification of PAI-1 polymorphism.
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